#BEGIN_DRUGCARD DB01743

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C55H85N17O22

# Chemical_IUPAC_Name:
3-{[(1R,4aS)-1-{[(1S)-1-{[(1R)-1-{[(1S)-1-{[(1R)-1-{[(3R,6R,9R,12R)-3,6-bis[(1R)-1-hydroxyethyl]-9-[3-(N-hydroxyformamido)propyl]-2,5,8,11-tetraoxo-1,4,7,10-tetraazacyclohexadecan-12-yl]carbamoyl}-4-(N-hydroxyformamido)butyl]carbamoyl}-2-hydroxyethyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}-2-hydroxyethyl]carbamoyl}-8,9-dihydroxy-1H,2H,3H,4H,4aH-pyrimido[1,2-a]quinolin-5-yl]carbamoyl}propanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Pyoverdine-Chromophore

# HET_ID:
PVD

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C55H85N17O22/c1-27(77)43-53(91)59-15-4-3-8-30(46(84)63-33(11-7-19-71(94)26-76)49(87)68-44(28(2)78)54(92)69-43)62-47(85)32(10-6-18-70(93)25-75)65-50(88)35(23-73)66-48(86)31(9-5-16-60-55(56)57)64-51(89)36(24-74)67-52(90)37-14-17-58-45-34(61-41(81)12-13-42(82)83)20-29-21-39(79)40(80)22-38(29)72(37)45/h20-22,25-28,30-33,35-37,43-45,58,73-74,77-80,93-94H,3-19,23-24H2,1-2H3,(H,59,91)(H,61,81)(H,62,85)(H,63,84)(H,64,89)(H,65,88)(H,66,86)(H,67,90)(H,68,87)(H,69,92)(H,82,83)(H4,56,57,60)/t27-,28-,30-,31-,32-,33-,35+,36+,37-,43-,44-,45+/m1/s1

# InChI_Key:
InChIKey=IXTLVPXCZJJUQB-BXEOTLQGSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1743

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
1336.3641

# Molecular_Weight_Mono:
1335.605507489

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1XKH

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.7

# Predicted_LogS:
-2.9

# Predicted_Water_Solubility:
1.62e+00 g/l

# Primary_Accession_No:
DB01743

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936203

# PubChem_Substance_ID:
46507877

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02706

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C[C@@H](O)[C@H]1NC(=O)[C@H](NC(=O)[C@@H](CCCN(O)C=O)NC(=O)[C@@H](CCCCNC1=O)NC(=O)[C@@H](CCCN(O)C=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H]1CCN[C@H]2N1C1=CC(O)=C(O)C=C1C=C2NC(=O)CCC(O)=O)[C@@H](C)O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:27 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cell outer membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
L10210

# Drug_Target_1_GenBank_ID_Protein:
294361

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
fpvA

# Drug_Target_1_Gene_Sequence:
>2442 bp
ATGCCAGCACCACACGGTCTCAGTCCTCTGAGTAAGGCGTTTTTGATGCGCCGTGCCTTC
CAACGCAGGATTCTTCCCCACTCGCTCGCCATGGCCCTGAGCCTGCCGCTGGCGGGATAT
GTCCAGGCGCAGGAAGTCGAGTTCGACATCCCTCCCCAGGCGCTGGGCAGCGCACTCCAG
GAGTTCGGCCGCCAGGCGGATATCCAGGTGCTGTATCGCCCGGAAGAGGTCCGGAACAAG
CGTAGCAGTGCGATCAAGGGCAAGCTGGAGCCGAACCAGGCGATTACCGAGCTGCTTCGT
GGCACCGGCGCATCGGTGGACTTCCAGGGCAATGCGATAACCATCAGCGTCGCCGAGGCG
GCGGACAGCAGCGTCGATCTCGGCGCCACCATGATCACCTCCAACCAGTTGGGCACCATC
ACCGAGGACAGCGGCTCCTATACGCCAGGCACTATCGCCACGGCGACCCGCCTGGTCCTG
ACTCCGCGCGAGACGCCCCAGTCGATCACCGTGGTCACCCGCCAGAACATGGACGACTTC
GGCCTCAACAACATCGACGACGTCATGCGCCATACGCCGGGCATCACCGTCTCGGCCTAC
GACACTGACCGCAACAACTACTATGCCCGCGGCTTCTCGATCAACAACTTCCAGTACGAC
GGGATTCCCTCGACGGCCCGCAACGTCGGCTACTCCGCGGGCAATACGCTCAGTGACATG
GCCATCTACGACCGGGTGGAAGTACTCAAGGGGGCGACCGGCCTGCTCACCGGTGCGGGG
TCCCTCGGCGCCACGATCAACCTGATCCGCAAGAAACCTACCCATGAATTCAAGGGCCAT
GTCGAACTGGGCGCGGGCAGTTGGGACAATTACCGCTCCGAACTGGACGTCAGCGGCCCA
CTGACCGAGTCCGGCAACGTCCGCGGCCGGGCGGTAGCCGCCTACCAGGATAAGCACTCG
TTCATGGATCACTACGAGCGCAAAACCAGCGTCTATTACGGCATCCTCGAGTTCGATCTG
AATCCCGACACCATGCTTACCGTCGGCGCCGACTATCAGGACAACGATCCCAAGGGATCG
GGCTGGTCGGGCAGCTTCCCGCTCTTCGACAGCCAGGGCAACCGCAACGACGTCTCCCGC
TCCTTCAACAACGGAGCCAAGTGGAGCAGTTGGGAGCAGTACACCCGCACCGTCTTCGCC
AACCTCGAGCACAATTTCGCCAACGGCTGGGTCGGCAAGGTGCAACTCGATCACAAGATC
AACGGTTACCACGCGCCCCTCGGCGCGATCATGGGCGACTGGCCGGCACCGGACAACAGC
GCCAAGATCGTTGCGCAGAAGTACACCGGCGAAACCAAGAGCAACTCGCTGGATATCTAT
CTCACCGGCCCCTTCCAGTTCCTCGGTCGCGAGCACGAGCTGGTGGTCGGCACCTCGGCT
TCCTTCTCCCACTGGGAGGGCAAGAGCTACTGGAACCTGCGCAACTACGACAACACCACC
GACGACTTCATCAACTGGGACGGCGATATAGGCAAGCCCGACTGGGGTACCCCCTCCCAG
TACATCGATGACAAGACCCGCCAGTTGGGCAGCTACATGACCGCCCGCTTCAATGTGACC
GATGACCTGAACCTGTTCCTAGGTGGACGCGTGGTCGACTACCGGGTAACCGGCCTGAAT
CCGACCATTCGCGAGTCCGGACGCTTCATTCCCTACGTCGGCGCGGTCTACGACCTGAAC
GATACCTACTCCGTCTACGCCAGCTATACCGACATCTTCATGCCGCAGGACAGTTGGTAT
CGCGACAGCAGCAACAAGCTGCTCGAACCCGACGAAGGCCAGAACTACGAGATCGGCATC
AAGGGTGAATATCTCGACGGACGACTCAATACCAGTCTCGCCTACTTCGAGATTCATGAG
GAAAACCGCGCGGAGGAAGACGCCCTCTACAACAGCAAACCGACCAACCCCGCCATCACC
TACGCCTACAAGGGCATCAAGGCCAAGACCAAGGGCTACGAGGCGGAAATCTCGGGTGAA
CTGGCGCCAGGCTGGCAGGTTCAGGCTGGCTATACCCACAAGATCATTCGCGACGACAGT
GGCAAGAAGGTTTCCACCTGGGAGCCTCAGGACCAGTTGAGCCTCTTCACCAGCTACAAG
TTCAAGGGCGCCCTGGACAAGCTCACGGTCGGCGGCGGCGCCCGCTGGCAGGGCAAGAGC
TGGCAGATGGTCAATCCCCGCAGACGCTGGGAAAAGTTCTCCCAGGAAGACTACTGGCTG
GTGGACCTGATGGCCCGCTACCAGATCACCGACAAGCTGTCAGCCAGCGTCAACGTCAAC
AACGTCTTCGACAAGACCTACTACACCAACATCGGTTTCTACACCTCGGCATCCTATGGC
GATCCACGGAACCTGATGTTCAGCACTCGCTGGGACTTCTGA

# Drug_Target_1_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_1_General_References:
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.
8335619	Poole K, Neshat S, Krebes K, Heinrichs DE: Cloning and nucleotide sequence analysis of the ferripyoverdine receptor gene fpvA of Pseudomonas aeruginosa. J Bacteriol. 1993 Aug;175(15):4597-604.
8918232	McMorran BJ, Merriman ME, Rombel IT, Lamont IL: Characterisation of the pvdE gene which is required for pyoverdine synthesis in Pseudomonas aeruginosa. Gene. 1996 Oct 17;176(1-2):55-9.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2387

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
91168

# Drug_Target_1_Name:
Ferripyoverdine receptor

# Drug_Target_1_Number_of_Residues:
815

# Drug_Target_1_PDB_ID:
1XKH

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00593	TonB_dep_Rec
PF07660	STN
PF07715	Plug

# Drug_Target_1_Protein_Sequence:
>Ferripyoverdine receptor precursor
MPAPHGLSPLSKAFLMRRAFQRRILPHSLAMALSLPLAGYVQAQEVEFDIPPQALGSALQ
EFGRQADIQVLYRPEEVRNKRSSAIKGKLEPNQAITELLRGTGASVDFQGNAITISVAEA
ADSSVDLGATMITSNQLGTITEDSGSYTPGTIATATRLVLTPRETPQSITVVTRQNMDDF
GLNNIDDVMRHTPGITVSAYDTDRNNYYARGFSINNFQYDGIPSTARNVGYSAGNTLSDM
AIYDRVEVLKGATGLLTGAGSLGATINLIRKKPTHEFKGHVELGAGSWDNYRSELDVSGP
LTESGNVRGRAVAAYQDKHSFMDHYERKTSVYYGILEFDLNPDTMLTVGADYQDNDPKGS
GWSGSFPLFDSQGNRNDVSRSFNNGAKWSSWEQYTRTVFANLEHNFANGWVGKVQLDHKI
NGYHAPLGAIMGDWPAPDNSAKIVAQKYTGETKSNSLDIYLTGPFQFLGREHELVVGTSA
SFSHWEGKSYWNLRNYDNTTDDFINWDGDIGKPDWGTPSQYIDDKTRQLGSYMTARFNVT
DDLNLFLGGRVVDYRVTGLNPTIRESGRFIPYVGAVYDLNDTYSVYASYTDIFMPQDSWY
RDSSNKLLEPDEGQNYEIGIKGEYLDGRLNTSLAYFEIHEENRAEEDALYNSKPTNPAIT
YAYKGIKAKTKGYEAEISGELAPGWQVQAGYTHKIIRDDSGKKVSTWEPQDQLSLYTSYK
FKGALDKLTVGGGARWQGKSWQMVYNNPRSRWEKFSQEDYWLVDLMARYQITDKLSASVN
VNNVFDKTYYTNIGFYTSASYGDPRNLMFSTRWDF

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-43

# Drug_Target_1_Specific_Function:
Receptor for the siderophore ferripyoverdine

# Drug_Target_1_SwissProt_ID:
P48632

# Drug_Target_1_SwissProt_Name:
FPVA_PSEAE

# Drug_Target_1_Synonyms:
Ferripyoverdine receptor precursor

# Drug_Target_1_Theoretical_pI:
5.28

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01743
